Adding pertuzumab to existing treatments after surgery for early breast cancer not cost effective, says NICE in draft guidance
Women with a type of early breast cancer may not benefit from continuing or starting a drug after having surgery, NICE says in draft guidance.
Therapy offered within one month to prevent PTSD, says NICE
People who have suffered trauma and are at risk of post-traumatic stress disorder (PTSD) should be offered therapy within one month, NICE says in new draft guidance.
Professor David Haslam is knighted for his services to NHS Leadership
David has been honoured in Her Majesty, the Queen’s birthday honours list to recognise his outstanding achievements in NHS Leadership.
Takeda pioneers NICE’s new service for economic model review
NICE Scientific Advice (NSA) launched a new health economic model review service, PRIMA, in December 2017 and it is already proving to be a valuable resource for model developers.
Latest news headlines
-
Life-extending lung cancer drug will be more widely available on the NHS after NICE review
NICE says more people should be able to freely access pembrolizumab, known as Keytruda, after a new trial shows it helps certain adults with lung cancer live more than a year longer.
06 June 2018
-
NICE approves multiple sclerosis drugs after prices are reduced
Reductions to the price of three multiple sclerosis (MS) drugs mean NICE is now able to recommend them for routine NHS funding.
14 May 2018
-
New guidance will help combat drug resistant urinary tract infections, says NICE
NICE has published new guidance to help healthcare professionals optimise the treatment of urinary tract infections (UTIs).
08 May 2018
-
Hundreds of people with blood cancer given more treatment options after NICE recommends three drugs
NICE has recommended three blood cancer drugs, brentuximab vedotin, midostaurin and arsenic trioxide be made available on the NHS.
04 May 2018
-
Long term benefit of neuroblastoma treatment is too uncertain, says NICE
NICE has published draft guidance in which dinutuximab beta is not recommended as a treatment for high-risk neuroblastoma – a rare type of cancer that mainly affects children and young people.
04 May 2018
-
NICE appoints new head of health technology evaluation
NICE has announced that Meindert Boysen has been appointed as its director of the Centre for Health Technology Evaluation.
26 April 2018